Stockscreener 앱 받기
1.45
4.61%
-0.07
전일 마감가:
$1.52
열려 있는:
$1.51
하루 거래량:
4.40M
Relative Volume:
1.02
시가총액:
$474.61M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-5.3704
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
-12.65%
1개월 성능:
+5.84%
6개월 성능:
+35.51%
1년 성능:
+88.51%
1일 변동 폭
$1.45
$1.54
1주일 범위
$1.45
$1.65
52주 변동 폭
$0.515
$1.96
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.45 | 497.53M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 - MyChesCo
Macro Review: Is Ocugen Inc forming a double bottom2025 Volatility Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ocugen Stock: A Turnaround Fueled by Promising Trial Data - AD HOC NEWS
Ocugen’s Clinical Pipeline Takes Center Stage Following Capital Raise - AD HOC NEWS
How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance
Ocugen Secures Financial Runway Through Strategic Capital Raise - AD HOC NEWS
Ocugen Secures Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Ocugen Secures Funding at a Short-Term Cost to Shareholders - AD HOC NEWS
Ocugen Shares Defy Dilution Fears on Strong Clinical Data - AD HOC NEWS
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - Sahm
Ocugen closes $22.5 million registered direct offering By Investing.com - Investing.com South Africa
Ocugen Secures Financial Runway Through 2026 - AD HOC NEWS
How Fresh Capital And Positive OCU410 Data At Ocugen (OCGN) Has Changed Its Investment Story - Yahoo Finance
Ocugen strengthens balance sheet with new equity financing - TipRanks
Ocugen, Inc. Closes $22.5 Million Stock Offering - TradingView
Ocugen closes $22.5 million registered direct offering - Investing.com
Ocugen (NASDAQ: OCGN) reports strong midstage data for gene therapy - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
Ocugen Announces $22.5 Million Public Stock Offering - The Globe and Mail
Ocugen (NASDAQ:OCGN) Trading 12.4% HigherTime to Buy? - MarketBeat
Ocugen Stock Faces Dilution After Capital Raise - AD HOC NEWS
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy - MyChesCo
Ocugen prices $22.5 million common stock offering at $1.50 per share - Investing.com Nigeria
Ocugen prices $22.5 million common stock offering at $1.50 per share By Investing.com - Investing.com South Africa
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen Signs Underwriting Agreement With Oppenheimer & Co - TradingView
Form 424B5 Ocugen, Inc. - StreetInsider
Ocugen shares slide after company prices $22.5 million equity raise - MSN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Ocugen, Inc.
Ocugen (OCGN) Prices $22.5 Million Stock Offering - GuruFocus
Ocugen drops on stock offering - TradingView
Ocugen (OCGN) Prices Stock Offering to Raise $22.5 Million - GuruFocus
Ocugen stock falls after pricing $22.5 million common share offering By Investing.com - Investing.com Nigeria
Ocugen stock falls after pricing $22.5 million common share offering - Investing.com
Ocugen Announces Pricing Of $22.5 Million Offering Of Common Stock - TradingView
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen (OCGN) Is Down 12.6% After Positive Phase 2 OCU410 Data in Geographic Atrophy - simplywall.st
Gene therapy slows vision loss in Stargardt trial, fueling hope for first treatment - MSN
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment - mychesco.com
Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
OCGN Analyst Rating Maintains "Buy" with $7.00 Price Target | OC - GuruFocus
Aug Rallies: Is Ocugen Inc undervalued by DCF analysisEarnings Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update - MarketBeat
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):